Epilepsy
is associated with disrupted activities in the brain called seizures,
which affects the central nervous system. Epilepsy is categorized
into generalized seizures and partial seizures based on the areas
affected in the brain. Generalized seizures affect the whole brain,
while partial seizures affect just one part of the brain. Seizures
are further classified into mild seizures and stronger seizures
depending on the severity of the seizures. The diagnosis of mild
seizures are difficult, as its lasts only for few seconds. Stronger
seizures may last for a few seconds to several minutes, resulting in
spasms and uncontrollable muscle twitches. This may cause the patient
to lose consciousness, lead to temporary loss of cognition, or memory
loss during the seizure. Epilepsy occurring due to brain infections
such as meningitis is known as symptomatic epilepsy, while genetics
related condition is called idiopathic epilepsy.
Request
For Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/1701
Antiepileptic
Drugs Market Drivers
Factors
such as rising prevalence of epilepsy and robust pipeline are
expected to boost the market growth over the forecast period.
According to the study by Epilepsy Action Australia statistics in
2017, around 50 million people globally have epilepsy with around 80%
of the people living in emerging economies such as India, Brazil, and
China. Moreover, according to the Centers for Disease Control and
Prevention, in 2017, an estimated 3.4 million people have active
epilepsy in the U.S., which includes 3 million adults and 470,000
children. Manufacturers have potential drug molecules in the pipeline
for the treatment of various forms of epilepsy. For instance, SK Life
Sciences, Inc. has Cenobamate (YKP3089) in Phase 3 clinical trials.
Eisai, Co., Ltd. has the drug Perampanel in Phase 2 clinical trials,
and Marinus Pharmaceuticals, Inc. has the drug Ganaxolone in Phase II
clinical trials. The expected launches of these drugs over the
forecast period is expected to create favorable condition for the
market growth.
Antiepileptic
Drugs Market Regional Analysis
North
America and Europe are expected to witness significant growth in the
market over the forecast period due to robust pipeline for epilepsy
treatment and individual efforts by leading manufacturers. For
instance, Pfizer, Inc. entered into partnership with Epilepsy
Foundation to find solutions for generic forms of epilepsy and
associated neurological disorders in 2014. Asia Pacific region is
expected to show positive developments over the forecast period,
owing to drug launches by leading manufacturers in the region. For
instance, UCB Pharma received approval in Japan for Vimpat adjunctive
therapy for partial onset seizures of epilepsy in 2016. Moreover,
Eisai Pharma launched antiepilepsy drug Fycompa in India in 2017.
Antiepileptic
Drugs Market Competitive Landscape
Key
players operating in the global antiepileptic drugs market include
GlaxoSmithKline plc, Johnson & Johnson, Valeant Pharmaceuticals
International, Inc., Abbott Laboratories, Cephalon, Inc., Pfizer,
Inc., Sunovion Pharmaceuticals, Inc., Novartis AG, UCB Pharma Ltd.,
and Sanofi S.A.
Antiepileptic
Drugs Market Taxonomy
The
global antiepileptic drugs market is segmented on the basis of drug
class, distribution channel, and region:
By
Drug Class
-
First Generation
-
Second Generation
-
Third Generation
Browse
Complete Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/antiepileptic-drugs-market-1701
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment